ArticleBMC cancer2025
Immunohistochemical expression of tumor-infiltrating lymphocytes CD8 and FOXP3 in invasive ductal carcinoma of breast.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic Significance of the Tumour Microenvironment in Surgically Resected Canine Pulmonary Adenocarcinomas.Veterinary and comparative oncology · 2026Article
- The Interplay of CD8+ TILs and Microvascular Density: A Novel Prognostic Indicator in Colorectal Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- The Impact of Microsatellite Instability and CD8+ Tumor Infiltrating Lymphocytes on Neoadjuvant Chemotherapy Response in Colorectal Cancer: A Prospective Observational Study.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-infiltrating lymphocytes (TILs) in breast cancer primarily comprise CD8+ T cells, which have anti-tumor properties, and FOXP3+ regulatory T cells (Tregs), which act as immune regulators. Both of these lymphocyte types play a significant role in breast cancer immunity. Understanding the relationship between TIL levels and the balance between CD8+ and FOXP3+ T cells is crucial for breast cancer management. Despite the growing recognition of their importance, the precise role and impact of these immune cells remain controversial and not fully understood. Evaluating the infiltration of CD8+ T cells and FOXP3+ Tregs in breast cancer tissues, as well as their correlation with tumor characteristics, can provide valuable insights into their prognostic value and their impact on cancer progression. Such a study has not yet been reported in India. Therefore, this study explores the connection between TILs, FOXP3/CD8, and various clinicopathological parameters, aiming to better understand these relationships and improve prognostic models and personalized immunotherapy for breast cancer patients.
aimTo evaluate the immunohistochemical expression of TILs, CD8, and FOXP3 in invasive ductal carcinoma of the breast and analyze their association with clinicopathological parameters. MATERIALS AND
methodsNinety-six histologically proven cases of Infiltrating ductal carcinoma (IDC) Breast were studied. Age, Laterality, tumor size, TNM stage, lymph node metastasis, histological grade, ER, PR, HER2neu, and Ki67 status were done. Both intensity and proportion of CD8 and FOXP3 expression were recorded. STATISTICAL ANALYSIS: For qualitative data, the Chi-square test was used as a test of significance. The p-value (probability that the result is true) of < 0.05 was considered statistically significant after assuming all the rules of statistical tests.
resultsThere was an inverse correlation between CD8+ and FOXP3+ TILs (Pearson = − 0.508, p = 0.002), and a positive correlation between CD8+ TILs and overall TIL levels (Pearson = 0.419, p < 0.001). FOXP3+ TILs strongly correlated with a higher FOXP3/CD8 ratio (Pearson = 0.751, p < 0.001). These results suggest that higher CD8+ TILs are linked to robust anti-tumor immunity, while increased FOXP3+ TILs indicate an immunosuppressive environment. These insights highlight the importance of TIL balance in breast cancer prognosis and therapy.
conclusionThis study investigated links between clinical and tumor immunity, spotlighting CD8 and FOXP3 and their ratio. The immunohistochemical analysis of tumor-infiltrating lymphocytes CD8 and FOXP3 in invasive ductal carcinoma of the breast reveals crucial insights into the tumor microenvironment. These findings highlights the potential of immune markers not only in refining prognostic models but also in guiding personalized immunotherapeutic approaches for breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.